Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin versus rosuvastatin effects on oxidative stress markers in type 2 diabetes
IRCT20231122060137N2Phase 3Recruiting
- Sponsor
- Kerman University of Medical Sciences
- Start
- Aug 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of atorvastatin and rosuvastatin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Kerman University of Medical Sciences. Primary endpoints: Oxidative stress, Antioxidants and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
atorvastatinrosuvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20231122060137N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231122060137N2.